CLINICAL TRIALS PROFILE FOR DESCOVY

All Clinical Trials for DESCOVY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	CIHR Canadian HIV Trials Network	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	Gilead Sciences	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	San Raffaele University Hospital, Italy	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	University of Modena and Reggio Emilia	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	University Health Network, Toronto	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.

Clinical Trial Conditions for DESCOVY

Condition Name

Condition Name for DESCOVY
Intervention	Trials
HIV	5
HIV Prevention	3
HIV Infections	2
HIV-1-infection	2

Condition MeSH

Condition MeSH for DESCOVY
Intervention	Trials
HIV Infections	3
COVID-19	1
Cognitive Dysfunction	1
Coronavirus Infections	1

Clinical Trial Locations for DESCOVY

Trials by Country

Trials by Country for DESCOVY
Location	Trials
United States	21
South Africa	4
Canada	3
Thailand	3
Netherlands	2

Trials by US State

Trials by US State for DESCOVY
Location	Trials
California	3
Texas	2
Pennsylvania	2
Colorado	2
Maryland	1

Clinical Trial Progress for DESCOVY

Clinical Trial Phase

Clinical Trial Phase for DESCOVY
Clinical Trial Phase	Trials
PHASE1	2
Phase 4	5
Phase 3	4

Clinical Trial Status

Clinical Trial Status for DESCOVY
Clinical Trial Phase	Trials
Recruiting	8
Not yet recruiting	5
Completed	3

Clinical Trial Sponsors for DESCOVY

Sponsor Name

Sponsor Name for DESCOVY
Sponsor	Trials
Gilead Sciences	9
Hospital Universitari de Bellvitge	3
CONRAD	2

Sponsor Type

Sponsor Type for DESCOVY
Sponsor	Trials
Other	57
Industry	10
U.S. Fed	1

Last updated: July 28, 2026

Descovy (emtricitabine/tenofovir alafenamide) Clinical Trials Update, Market Analysis, and Forecast

Executive summary: Descovy (emtricitabine 200 mg plus tenofovir alafenamide fumarate 25 mg) is a Gilead HIV franchise pillar for treatment and HIV pre-exposure prophylaxis (PrEP). The near-to-mid-term outlook is driven by (1) continued uptake of once-daily oral PrEP, (2) the launch and competitive displacement dynamics of long-acting HIV prevention candidates and generics in certain geographies, (3) guideline-concordant use constraints (notably exclusion of receptive vaginal sex for PrEP), and (4) ongoing clinical development aimed at expanding prevention and treatment positioning across subpopulations, including renal and bone-safety profiles.

---

What clinical trials are updating Descovy’s HIV PrEP and treatment indications?

PrEP: what the live evidence base is targeting

Gilead’s Descovy PrEP program has focused on real-world effectiveness and regimen durability rather than radically changing the underlying mechanism. The pivotal clinical foundation remains:

• DISCOVER (Descovy vs Truvada for men who have sex with men and transgender women): noninferiority for HIV prevention.
• DISCOVER continuation and implementation evidence that supports persistence, adherence, and safety monitoring.

Newer updates in HIV prevention generally cluster around:

• Adherence and discontinuation outcomes in routine practice.
• Safety in comorbid populations (renal impairment, older adults, chronic hepatitis coinfection).
• Pharmacokinetics and start-stop strategies aligned with evolving clinical guidance.

Treatment: what “maintenance” studies typically update

For HIV treatment, Descovy supports combination antiretroviral regimens. Clinical trial updates usually include:

• Switch studies from other nucleos(t)ide backbones to maintain viral suppression.
• Resistance evolution characterization in “virologic failure” cohorts.
• Longer follow-up for renal and bone markers tied to tenofovir alafenamide exposure.

How to read the trial updates for commercial impact

Market implications typically come from:

• Population expansion that converts eligibility into prescription volume.
• Safety signals that change prescriber comfort in renal risk patients.
• Adherence data that affects payer coverage and guideline uptake.

---

What is the current FDA label status of Descovy for HIV prevention and treatment?

Is Descovy approved as HIV PrEP?

Yes. Descovy is approved as a once-daily oral HIV PrEP regimen for reducing the risk of sexually acquired HIV infection in at-risk adults and adolescents except for people at risk from receptive vaginal sex (the label restriction is a key commercial constraint).

Does Descovy have a treatment indication?

Yes. Descovy is approved as part of antiretroviral treatment of HIV-1 infection in appropriate patient populations, typically in combination regimens.

Label restriction is a major demand determinant

The “no receptive vaginal sex” constraint materially affects addressable market in settings where vaginal transmission is a larger share of new HIV diagnoses. It pushes use toward:

• Men who have sex with men
• Transgender women
• High-risk partners in sexual networks where receptive vaginal sex risk is not the driver

---

Who are Descovy’s key competitors in HIV PrEP, and how does Descovy compare?

Oral PrEP comparators

• Truvada (emtricitabine/tenofovir disoproxil fumarate): long-standing standard with broad evidence.
• Other oral nucleos(t)ide combinations are less prominent in many high-volume markets, with Truvada being the primary share competitor.

Long-acting prevention threats

Long-acting injectable prevention candidates have been a strategic question for oral PrEP franchises:

• If injectable products achieve high adherence and payer coverage, oral declines can accelerate once uptake scales.
• Oral franchises retain value where injection access is limited, in populations needing rapid initiation, or where adherence support drives persistence.

Descovy differentiation

Commercial differentiation points are typically:

• Tenofovir alafenamide safety profile versus disoproxil fumarate (renal and bone markers)
• Tolerability that supports persistence in real-world practice

---

How big is the Descovy addressable market for HIV PrEP and what drives growth?

Demand drivers

• Expanded screening and linkage-to-care programs in high-incidence geographies.
• Improved adherence infrastructure (navigation services, refill programs, pharmacy partnerships).
• Guideline reinforcement that supports sustained prescription rather than episodic use.

Constraints

• Label restriction for receptive vaginal sex reduces penetration in certain demographics.
• Competition from Truvada remains a persistent pressure, even if prescribers prefer Descovy in renal/bone risk patients.
• Payer formularies and prior authorization can slow conversion from eligibility to sustained use.

---

What is the most plausible market growth path for Descovy through 2028-2032?

Base-case growth logic

A reasonable forward curve for oral PrEP leaders typically follows:

1. Steady share gains where clinician confidence and payer coverage are favorable.
2. Adherence/persistence-driven volume rather than purely new-user recruitment.
3. Gradual pressure from next-generation prevention modalities as they gain reimbursement, clinic workflow, and patient acceptance.

Upside scenarios

• Payer expansion that reduces restrictions.
• Expanded subpopulation guidance based on emerging clinical evidence.
• Lower acquisition costs or improved supply economics that support broader adoption.

Downside scenarios

• Faster-than-expected injectable uptake with favorable payers and access.
• Shifts in clinical preference driven by program-level outcomes rather than safety.

(No explicit numerical forecast is provided here because clinical trial update volume, reimbursement trajectory, and geographic adoption rates are not quantified in the available source set.)

---

What do clinical outcomes suggest about adherence, persistence, and discontinuation for Descovy?

Why persistence matters

PrEP market performance is usually less about one-time enrollment and more about:

• Refill continuity
• Pharmacy switching rates
• Trial-to-real-world adherence translation

Real-world factors that can change demand

• Clinician prescribing behavior based on safety monitoring thresholds
• Patient affordability and copay behavior
• Program support quality (reminders, lab scheduling, counseling)

---

How are payers, reimbursement, and formulary decisions shaping Descovy adoption?

Formulary dynamics

Oral PrEP adoption at scale depends on:

• Preferred status vs Truvada
• Step edits or prior authorization criteria (renal thresholds, risk assessment forms)
• Copay assistance policies

Forecast implication

Formulary access can flatten or accelerate uptake in a way that overwhelms incremental trial efficacy differences. The market projection therefore hinges on reimbursement stability more than on marginal clinical endpoints.

---

What patent and exclusivity factors affect Descovy’s future competitive pressure?

(This section is intentionally limited to high-level commercial implications because the user request is framed as clinical update and market projection, and no specific patent estate dates were provided.)

Why patent life matters for PrEP economics

• Oral PrEP franchises are exposed to generic entry risk in some regions when exclusivity and patent barriers clear.
• Generic erosion can be delayed or accelerated by litigation outcomes and “authorized generic” strategies.

Litigation-driven entry pacing

Where patent challenges proceed, the timetable can compress or expand market share transitions. These effects show up as:

• Pre-launch price resets
• Copay program changes
• Increased payer leverage for therapeutic substitution

---

What is the competitive landscape for Descovy globally?

Regional dynamics

• High-income markets: pricing power depends on payer tiering and competition intensity.
• Middle-income and procurement-heavy settings: tender structures and generic availability can dominate uptake more than brand clinical differentiation.
• High-incidence settings with limited diagnostic capacity: scale depends on program maturity and lab infrastructure.

Manufacturing and supply

Supply reliability can drive short-term volatility in prescription continuity, impacting persistence-based revenue.

---

Key Takeaways

• Descovy remains a core oral HIV prevention and treatment option, supported by a mature clinical evidence base and a safety profile that supports persistence.
• Market growth is driven mainly by real-world adherence infrastructure, guideline-aligned prescribing, and payer access, with label restriction for receptive vaginal sex as a material constraint on maximum addressable demand.
• Competitive pressure is likely to come from Truvada for oral share and from long-acting prevention candidates for future modality switching as reimbursement and access mature.
• Patent and exclusivity dynamics can accelerate competitive transitions; therefore, forecast sensitivity is highest around litigation and regulatory/tender environment changes.

---

FAQs

1. Does Descovy work for HIV PrEP in people at risk from receptive vaginal sex?

No. The FDA PrEP label excludes receptive vaginal sex risk.

2. How does Descovy’s renal and bone safety profile affect prescribing?

It can increase clinician comfort compared with tenofovir disoproxil fumarate options in renal or bone-risk patients, supporting persistence and share retention.

3. Will long-acting HIV prevention injections reduce Descovy demand?

They can, but impact depends on uptake, reimbursement, clinic workflow, and patient acceptance across geographies.

4. What role do payer formulary rules play in Descovy sales?

They determine whether eligible patients can start and continue therapy without delays, shaping persistence and the effective addressable market.

5. What clinical endpoints matter most for PrEP adoption?

Real-world adherence, discontinuation rates, and HIV incidence reduction in routine practice are the operational metrics that translate trial efficacy into market outcomes.

---

References (APA)

1. FDA. (n.d.). Descovy (emtricitabine; tenofovir alafenamide) prescribing information. U.S. Food and Drug Administration.
2. Gilead Sciences. (n.d.). Descovy clinical studies and supporting trial information. Gilead Sciences.
3. Centers for Disease Control and Prevention. (n.d.). Clinical guidance for HIV pre-exposure prophylaxis (PrEP). U.S. Department of Health and Human Services.